MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
We recently published a list of Jim Cramer Discusses These 10 Stocks & President Trump’s Tariffs. In this article, we are ...
Hershey beat fourth-quarter profit and sales estimates as the chocolate maker's price hikes helped offset the higher cost of cocoa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results